載入中
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
前收盤價
US$2.72
−US$0.03 · -1.09%
盤中時間採用ET。市場資料可能有所延遲。
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
日內區間
目前US$2.72
52週區間
目前US$2.72
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
48
合理估值
情緒
44
多空交錯
風險
66
高風險
動能
16
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
日內區間
目前US$2.72
52週區間
目前US$2.72
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 6693 USD | 1.5萬 USD | 2.56萬 USD | 2.25萬 USD |
| 毛利 | — | −6693 USD | −1.5萬 USD | −2.56萬 USD | −2.25萬 USD |
| 研究與開發 | 942.87萬 USD | 1053.54萬 USD | 1761.66萬 USD | 1151.01萬 USD | 897.09萬 USD |
| 銷售、一般及管理費用 | 608.69萬 USD | 1063.2萬 USD | 1344.4萬 USD | 1229.51萬 USD | 1167.67萬 USD |
| 營業費用 | 1551.56萬 USD | 2116.75萬 USD | 3106.06萬 USD | 2380.51萬 USD | 2064.76萬 USD |
| 利息收入 | — | 6.36萬 USD | 21.51萬 USD | 9.01萬 USD | 5133 USD |
| 利息支出 | 73.99萬 USD | — | — | — | — |
| 折舊和攤銷 | — | 6693 USD | 1.5萬 USD | 2.56萬 USD | 2.25萬 USD |
| 營業利益 | −1551.56萬 USD | −2117.42萬 USD | −3107.56萬 USD | −2383.07萬 USD | −2067.01萬 USD |
| 淨利 | −1622.9萬 USD | −2111.12萬 USD | −3086.05萬 USD | −2374.06萬 USD | −2066.5萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
